| Task |
Description |
1 |
2 |
3 |
4 |
5 |
6 |
7 |
8 |
9 |
10 |
11 |
12 |
13 |
14 |
15 |
16 |
17 |
18 |
| WP1.1 |
Complexes in the ubiquitination pathway |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 1.1.1 |
Identification and characterisation of targets |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 1.1.2 |
Co-expression screening of components |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 1.1.3 |
Optimisation of complexes +/- target and ubiquitin |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 1.1.4 |
Scale-up and QA of first set of suitable samples |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 1.1.5 |
Screen crystallization and NMR of first complexes |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 1.1.6 |
Progress first complexes into structure determination |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| D1.1.1 |
Construct design and expression data for protein domains |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| D1.1.2 |
Expression data for complexes |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| D1.1.3 |
Expression and QA for protein domains |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| D1.1.4 |
Biophysical data for complexes |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| M1.1.1 |
Expression of complexes |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| M1.1.2 |
First purified protein domains |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| M1.1.3 |
First set of stable complexes into crystn and NMR screens |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Task |
Description |
1 |
2 |
3 |
4 |
5 |
6 |
7 |
8 |
9 |
10 |
11 |
12 |
13 |
14 |
15 |
16 |
17 |
18 |
| WP1.2 |
Cell life,
death and integrity |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 1.2.1 |
Co-expression
screening in E.coli of
protein complexes |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 1.2.2 |
Expression
screening of complexes in eukaryotic systems |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 1.2.3 |
Use of truncation
libraries to identify soluble domains |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 1.2.4 |
Scale-up and QA
of suitable samples |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 1.2.5 |
Assess assembly
and stability of complexes biophysically |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 1.2.6 |
Screen crystn properties and NMR spectra |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 1.2.7 |
Progress first
targets into structure determination |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| D1.2.1 |
Expression data
for components and complexes |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| D1.2.2 |
Biophysical data
for complexes and components |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| M1.2.1 |
Expression of
some components and complexes |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| M1.2.2 |
Characterisation
of first components and complexes |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| M1.2.3 |
Start
crystallization trials and NMR screening |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Task |
Description |
1 |
2 |
3 |
4 |
5 |
6 |
7 |
8 |
9 |
10 |
11 |
12 |
13 |
14 |
15 |
16 |
17 |
18 |
| WP1.3 |
Complexes in
development and synaptic signalling |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 1.3.1 |
Co-expression
screening in E.coli of
protein complexes |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 1.3.2 |
Expression
screening of complexes in eukaryotic systems |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 1.3.3 |
Co-expression
screening of problematic molecules |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 1.3.4 |
Use of truncation
libraries for soluble domains |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 1.3.5 |
Scale-up, 15N
and 13C labelling and QA of samples |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 1.3.6 |
Analyse
intrinsically disordered cytoplasmic domains |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 1.3.7 |
Screen crystn and NMR samples in first targets |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 1.3.8 |
Progress first
targets into structure determination |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| D1.3.1 |
Expression data
for some components and complexes |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| D1.3.2 |
Biophysical data
for first set of complexes |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| M1.3.1 |
Purification and
labelled samples of first proteins |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| M1.3.2 |
Characterisation
of first samples and X-ray/NMR screens |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Task |
Description |
1 |
2 |
3 |
4 |
5 |
6 |
7 |
8 |
9 |
10 |
11 |
12 |
13 |
14 |
15 |
16 |
17 |
18 |
| WP1.4 |
Protein
kinases |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 1.4.1 |
Co-expression
screening of protein kinases and modulators |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 1.4.2 |
Expression
screening of IFNR extracellular domains |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 1.4.3 |
Co-expression
screening of IFNR extracellular
domains |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 1.4.4 |
Scale-up and QA
of suitable samples |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 1.4.5 |
Assess assembly
and stability of complexes biophysically |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 1.4.6 |
Screen cyrstn properties, SAXS and NMR spectra |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 1.4.7 |
Progress first
targets into structure determination |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| D1.4.1 |
Expression data
for some components and complexes |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| D1.4.2 |
Biophysical data
for first set of complexes |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| M1.4.1 |
Expression of
some components and complexes |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| M1.4.2 |
Characterisation
of first samples and X-ray/NMR screens |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Task |
Description |
1 |
2 |
3 |
4 |
5 |
6 |
7 |
8 |
9 |
10 |
11 |
12 |
13 |
14 |
15 |
16 |
17 |
18 |
| WP1.5 |
Protein
phosphatases |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 1.5.1 |
Multi-expression
screening of protein phosphatases |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 1.5.2 |
Scale-up and QA
of suitable samples |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 1.5.3 |
Assess assembly
and stability of complexes biophysically |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 1.5.4 |
Screen
crystallization properties of targets |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 1.5.5 |
Progress first
targets into structure determination |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| D1.5.1 |
Expression data
for some components and complexes |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| D1.5.2 |
Biophysical data
for first set of complexes |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| M1.5.1 |
Expression of
some components and complexes |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| M1.5.2 |
Characterisation
of first samples and X-ray/NMR screens |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Task |
Description |
1 |
2 |
3 |
4 |
5 |
6 |
7 |
8 |
9 |
10 |
11 |
12 |
13 |
14 |
15 |
16 |
17 |
18 |
| WP1.6 |
Transcription
complexes |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 1.6.1 |
Identn and charactn of target NR and TF assemblies |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 1.6.2 |
Co-expression
screening of components and complexes |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 1.6.3 |
Scale-up and QA
of first set of components and complexes |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 1.6.4 |
Biophysical
charactn of assemblies and complex stability |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 1.6.5 |
Screen
crystallization properties of first products |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 1.6.6 |
Progress first
products into structure determination |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| D1.6.1 |
Expression data
for first products |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| D1.6.2 |
Biophysical data
for first products |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| M1.6.1 |
Expression of
some components and complexes |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| M1.6.2 |
Characterisation
of first samples and X-ray/NMR screens |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Task |
Description |
1 |
2 |
3 |
4 |
5 |
6 |
7 |
8 |
9 |
10 |
11 |
12 |
13 |
14 |
15 |
16 |
17 |
18 |
| WP1.7 |
Innate immune
system |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 1.7.1 |
Selection of
complexes involved in pathogen recognition |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 1.7.2 |
Selection,
expression and optimisation of complexes |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 1.7.3 |
Purifn,
crystn and structure determination of complexes |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| D1.7.1 |
Cloning and
sequence verification of targets |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| D1.7.2 |
Expression of
>1target and assess expression/solubility |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| D1.7.3 |
Crystallization
trails of >1 target protein |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| M1.7.1 |
Cloning of
targets |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| M1.7.2 |
Analysis of
expression/ identify optimal route for solubility |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| M1.7.3 |
Obtain a soluble
expressed protein |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Task |
Description |
1 |
2 |
3 |
4 |
5 |
6 |
7 |
8 |
9 |
10 |
11 |
12 |
13 |
14 |
15 |
16 |
17 |
18 |
| WP1.8 |
Adaptive
immune system |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 1.8.1 |
Expression
screening of components in E. coli |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 1.8.2 |
Expression
screening of components in eukaryotic systems |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 1.8.3 |
Identification
and production of additional ligands |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 1.8.4 |
Co-expression of
any cytoplasmic targets |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 1.8.5 |
Scale-up and QA
of suitable samples |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 1.8.6 |
Characterise
recognition/binding properties of receptors |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 1.8.7 |
Screen
crystallization properties |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 1.8.8 |
Progress first
targets into structure determination |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| D1.8.1 |
Expression data
for some TCR, NKR & WAFL protein |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| D1.8.2 |
Biophysical data
for TCR, NKR & WAFL protein |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| M1.8.1 |
Expression data
for some TCR, NKR & WAFL protein |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| M1.8.2 |
Biophysical
charactn of binding properties of receptors |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Task |
Description |
1 |
2 |
3 |
4 |
5 |
6 |
7 |
8 |
9 |
10 |
11 |
12 |
13 |
14 |
15 |
16 |
17 |
18 |
| WP1.9 |
Viral
subversion of cell signals & immune modulation |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 1.9.1 |
Identn and charactn of target viral proteins and partners |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 1.9.2 |
Co-expression
screening of components and complexes |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 1.9.3 |
Optimisation of
stability for viral proteins with partners |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 1.9.4 |
Scale-up &
biophysical chractn of first suitable samples |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 1.9.5 |
Screen
crystallization properties of first viral products |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 1.9.6 |
Progress first
viral products into structure determination |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| D1.9.1 |
Expression data
for first viral proteins |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| D1.9.2 |
Biophysical data
for first viral proteins and complexes |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| M1.9.1 |
Expression of
viral proteins/complexes |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| M1.9.2 |
First set of
viral complexes into crystn and NMR screens |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|